CA2569542A1 - A delivery system - Google Patents

A delivery system Download PDF

Info

Publication number
CA2569542A1
CA2569542A1 CA002569542A CA2569542A CA2569542A1 CA 2569542 A1 CA2569542 A1 CA 2569542A1 CA 002569542 A CA002569542 A CA 002569542A CA 2569542 A CA2569542 A CA 2569542A CA 2569542 A1 CA2569542 A1 CA 2569542A1
Authority
CA
Canada
Prior art keywords
delivery system
core
membrane
cyclodextrins
regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002569542A
Other languages
French (fr)
Other versions
CA2569542C (en
Inventor
Teppo Riihimaeki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Oy
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34932022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2569542(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2569542A1 publication Critical patent/CA2569542A1/en
Application granted granted Critical
Publication of CA2569542C publication Critical patent/CA2569542C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a delivery system comprising a core and a membrane encasing said core, wherein said core and membrane consist essentially of an elastomer composition and said core comprises at least one therapeutically active agent. The delivery system is characterized in that the membrane comprises at least one regulating agent. The invention also relates to a method for controlling the release of at least one therapeutically active agent from a delivery system.

Claims (9)

1. A delivery system comprising a core and a membrane encas-ing said core, wherein said core and membrane consist essentially of an elastomer composition and said core comprises at least one therapeutically active agent, characterized in that the membrane comprises at least one regulating agent.
2. The delivery system according to claim 1, characterized in that said regulating agent is selected from the group consisting of carbo-hydrates, cyclodextrins and modified cyclodextrins.
3. The delivery system according to claim 2, characterized in that said regulating agent is selected from the group consisting of alpha cyclodextrins, beta cyclodextrins, gamma cyclodextrins, hydroxypro-pyl cyclodextrins, maltosyl .beta.-cyclodextrin and .beta.-cyclodextrin sulfobu-tyl.
4. The delivery system according to any of the previous claims, characterized in that the membrane comprises one regulating agent.
5. The delivery system according to any of the claims 1-3, -characterized in that the membrane comprises two regulating agents.
6. The delivery system according to claim 5, characterized in that said regulating agents are present in separate parts of said mem-brane.
7. The delivery system according to claim 5 or 6, characterized in that said regulating agents are present in separate layers of said membrane.
8. The delivery system according to any of the previous claims, characterized in that said delivery system is selected from the group consisting of transdermal patches, implants for releasing a therapeutically active agent in the body tissues, intravaginal rings, intracervical and intrauterine devices.
9. A method for controlling the release of at least one therapeuti-cally active agent from a delivery system comprising a core and a membrane encasing said core, wherein said core and membrane consist essentially of an elastomer composition and said core com-prises said at least one therapeutically active agent, characterized in that said regulation is performed by at least one regulating agent comprised in the membrane of said delivery system.
CA2569542A 2004-07-13 2005-07-05 A delivery system Expired - Fee Related CA2569542C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04396049.1 2004-07-13
EP04396049A EP1629844B2 (en) 2004-07-13 2004-07-13 A longterm delivery system with controlled initial burst
PCT/FI2005/000314 WO2006005794A1 (en) 2004-07-13 2005-07-05 A delivery system

Publications (2)

Publication Number Publication Date
CA2569542A1 true CA2569542A1 (en) 2006-01-19
CA2569542C CA2569542C (en) 2012-10-09

Family

ID=34932022

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2569542A Expired - Fee Related CA2569542C (en) 2004-07-13 2005-07-05 A delivery system

Country Status (24)

Country Link
US (1) US7850986B2 (en)
EP (1) EP1629844B2 (en)
JP (1) JP4881861B2 (en)
KR (1) KR20070035032A (en)
CN (1) CN1984639A (en)
AT (1) ATE372772T1 (en)
AU (1) AU2005261682B2 (en)
BR (1) BRPI0513295A (en)
CA (1) CA2569542C (en)
DE (1) DE602004008912T3 (en)
DK (1) DK1629844T4 (en)
ES (1) ES2293193T5 (en)
HK (1) HK1086751A1 (en)
IL (1) IL179846A (en)
MX (1) MX2007000433A (en)
NO (1) NO334931B1 (en)
NZ (1) NZ551823A (en)
PL (1) PL1629844T5 (en)
PT (1) PT1629844E (en)
RU (1) RU2412693C2 (en)
SI (1) SI1629844T1 (en)
UA (1) UA91337C2 (en)
WO (1) WO2006005794A1 (en)
ZA (1) ZA200610473B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629844B2 (en) 2004-07-13 2012-04-18 Bayer Schering Pharma Oy A longterm delivery system with controlled initial burst
EP2594259A1 (en) * 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US20140209100A1 (en) * 2011-07-20 2014-07-31 Patrick F. Kiser Intravaginal devices for drug delivery
KR102304995B1 (en) * 2012-01-18 2021-09-28 월드와이드 이노베이티브 헬쓰케어, 인코포레이티드 Kit and method of modifiable occlusive skin dressing
AR089765A1 (en) 2012-01-23 2014-09-17 Bayer Oy A SYSTEM FOR THE SUPPLY OF A PHARMACO
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
CN105310974B (en) * 2014-08-01 2019-08-23 山东绿叶制药有限公司 The implant of rotigotine and its derivative or its pharmaceutical salts

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832252A (en) 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
ATE86484T1 (en) 1987-08-08 1993-03-15 Akzo Nv CONTRACEPTIVE IMPLANT.
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
RU2088166C1 (en) 1993-08-10 1997-08-27 Педдер Валерий Викторович Method and device for carrying out contraception
CA2582666C (en) 1994-04-08 2010-05-25 Qlt Usa, Inc. Controlled release implant
US5492947A (en) * 1994-06-23 1996-02-20 Aspen Research Corporation Barrier material comprising a thermoplastic and a compatible cyclodextrin derivative
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
FI97947C (en) 1994-09-27 1997-03-25 Leiras Oy Process for the preparation of a pharmaceutical composition
GB9522403D0 (en) † 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
US6416778B1 (en) * 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
NZ330596A (en) * 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
WO1999061062A1 (en) † 1998-05-29 1999-12-02 Massachusetts Institute Of Technology Cyclodextrin complexes
AU6517900A (en) 1999-08-03 2001-02-19 Smith & Nephew, Inc. Controlled release implantable devices
PT1248596E (en) * 2000-01-11 2007-06-21 Bertex Pharma Gmbh Implantation kit comprising a support phase and a solvent
US6299894B1 (en) † 2000-05-10 2001-10-09 Leiras Oy Drug delivery device, especially for the delivery of gestodene
WO2002032433A1 (en) * 2000-10-20 2002-04-25 Leiras Oy Drug delivery system
WO2002076426A2 (en) 2001-03-27 2002-10-03 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
CN1210079C (en) 2001-04-25 2005-07-13 上海市计划生育科学研究所 Medicine for vaginal ring and its application
CN1289064C (en) 2001-08-31 2006-12-13 先灵有限责任公司 Drug delivery system
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
CA2531640C (en) † 2003-07-10 2013-06-18 Galen (Chemicals) Limited Intravaginal drug delivery devices
BRPI0509146B8 (en) * 2004-03-24 2021-05-25 Merck Sharp & Dohme drug delivery system, method of manufacturing the same, and use of the drug delivery system
EP1629844B2 (en) 2004-07-13 2012-04-18 Bayer Schering Pharma Oy A longterm delivery system with controlled initial burst

Also Published As

Publication number Publication date
US7850986B2 (en) 2010-12-14
DE602004008912T2 (en) 2008-06-05
AU2005261682B2 (en) 2010-02-11
WO2006005794A1 (en) 2006-01-19
NO20070805L (en) 2007-02-12
BRPI0513295A (en) 2008-05-06
ZA200610473B (en) 2008-06-25
MX2007000433A (en) 2007-03-07
SI1629844T1 (en) 2007-12-31
DK1629844T3 (en) 2007-10-15
DK1629844T4 (en) 2012-05-29
NZ551823A (en) 2008-07-31
NO334931B1 (en) 2014-07-14
ES2293193T5 (en) 2012-06-13
EP1629844A1 (en) 2006-03-01
PL1629844T5 (en) 2012-10-31
RU2006145900A (en) 2008-06-27
JP2008506672A (en) 2008-03-06
EP1629844B1 (en) 2007-09-12
PT1629844E (en) 2007-10-17
UA91337C2 (en) 2010-07-26
IL179846A (en) 2012-07-31
PL1629844T3 (en) 2008-02-29
ES2293193T3 (en) 2008-03-16
ATE372772T1 (en) 2007-09-15
JP4881861B2 (en) 2012-02-22
US20080031922A1 (en) 2008-02-07
CN1984639A (en) 2007-06-20
DE602004008912T3 (en) 2012-09-13
IL179846A0 (en) 2007-05-15
EP1629844B2 (en) 2012-04-18
AU2005261682A1 (en) 2006-01-19
CA2569542C (en) 2012-10-09
RU2412693C2 (en) 2011-02-27
KR20070035032A (en) 2007-03-29
HK1086751A1 (en) 2006-09-29
DE602004008912D1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
CA2569542A1 (en) A delivery system
AU2003258331A1 (en) Drug eluting coatings for medical implants
Haas et al. Antibiotic prophylaxis in dermatologic surgery
US5694947A (en) Intravaginal delivery system
KR20100090708A (en) Vaginal delivery system
TR200200562T2 (en) Pharmaceutical compositions for oral release that can be secreted in the body in a controlled manner and prevent unpleasant taste
WO2007150018A3 (en) Steroid-containing sustained release intraocular implants and related methods
CA2235919A1 (en) Non-polymeric sustained release delivery system
ATE368482T1 (en) IMPLANTS WITH FK506 FOR RESTENOSE TREATMENT AND PROPHYLAXIS
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
ATE317690T1 (en) LIQUID COMPOSITIONS FOR DRUG DELIVERY
BR0015346A (en) Pharmaceutical formulation containing tolterodine and its use
ATE318623T1 (en) COATED STENT FOR THE RELEASE OF ACTIVE SUBSTANCES
WO2006050091A3 (en) Bioactive wound dressings and implantable devices and methods of use
CY1108482T1 (en) DISTRIBUTION SYSTEM DISTRIBUTION, METHOD OF PREPARATION AND USE FOR THE TREATMENT OF CHolinergic Deficiency Disorders
JP2023159366A (en) Dextromethorphan transdermal delivery device
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
HU0000045D0 (en) Thin adhesive plaster treated by betamethasone- and hyaluronic acid- for treatment of psoriasis, dermatitis and dermatosis
PT2062569E (en) Vaginal delivery system
WO2007068487A3 (en) Tumour treatment with treg down-regulating active agents
WO2005082054A3 (en) Combinations for the treatment of fungal infections
ATE252895T1 (en) TRANSDERMAL THERAPEUTIC SYSTEM AND METHOD FOR THE PRODUCTION THEREOF

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831